Abbott Laboratories (NYSE:ABT) — Market Cap & Net Worth
Market Cap & Net Worth: Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) has a market capitalization of $177.76 Billion ($177.76 Billion) as of September 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #126 globally and #74 in its home market, demonstrating a -2.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abbott Laboratories's stock price $102.23 by its total outstanding shares 1738871947 (1.74 Billion). Also see Abbott Laboratories asset portfolio for a full breakdown of the balance sheet.
Abbott Laboratories Market Cap History: 2015 to 2026
Abbott Laboratories's market capitalization history from 2015 to 2026. Data shows growth from $65.91 Billion to $177.76 Billion (10.15% CAGR). Also see ABT cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Abbott Laboratories is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P 500 Index
GSPC
|
$62.97 Trillion | 0.48% | #59 of 503 |
|
S&P 100
OEX
|
$45.52 Trillion | 0.69% | #53 of 101 |
Weight: Abbott Laboratories's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abbott Laboratories Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abbott Laboratories's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ABT stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.91x
Abbott Laboratories's market cap is 4.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
33.39x
Abbott Laboratories's market cap is 33.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $57.79 Billion | $20.85 Billion | $1.40 Billion | 2.77x | 41.28x |
| 2017 | $87.85 Billion | $27.39 Billion | $477.00 Million | 3.21x | 184.18x |
| 2018 | $113.39 Billion | $30.58 Billion | $2.37 Billion | 3.71x | 47.88x |
| 2019 | $138.42 Billion | $31.90 Billion | $3.69 Billion | 4.34x | 37.54x |
| 2020 | $177.24 Billion | $34.61 Billion | $4.50 Billion | 5.12x | 39.43x |
| 2021 | $231.34 Billion | $43.08 Billion | $7.07 Billion | 5.37x | 32.72x |
| 2022 | $183.50 Billion | $43.65 Billion | $6.93 Billion | 4.20x | 26.47x |
| 2023 | $187.64 Billion | $40.11 Billion | $5.72 Billion | 4.68x | 32.79x |
| 2024 | $196.68 Billion | $41.95 Billion | $13.40 Billion | 4.69x | 14.68x |
| 2025 | $217.86 Billion | $44.33 Billion | $6.52 Billion | 4.91x | 33.39x |
Competitor Companies of ABT by Market Capitalization
Companies near Abbott Laboratories in the global market cap rankings as of September 19, 2026. Review ABT tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Abbott Laboratories by market ranking:
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #235 globally with a market cap of $107.45 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (XETRA:2M6): Ranked #323 globally with a market cap of $83.04 Billion USD ( €71.03 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.77 |
| #235 | Stryker Corporation | NYSE:SYK | $107.45 Billion | $280.13 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #323 | Medtronic PLC | XETRA:2M6 | $83.04 Billion | €69.20 |
Abbott Laboratories Historical Marketcap From 2015 to 2026
Between 2015 and today, Abbott Laboratories's market cap moved from $65.91 Billion to $ 177.76 Billion, with a yearly change of 10.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $177.76 Billion | -18.41% |
| 2025 | $217.86 Billion | +10.77% |
| 2024 | $196.68 Billion | +4.82% |
| 2023 | $187.64 Billion | +2.26% |
| 2022 | $183.50 Billion | -20.68% |
| 2021 | $231.34 Billion | +30.53% |
| 2020 | $177.24 Billion | +28.04% |
| 2019 | $138.42 Billion | +22.08% |
| 2018 | $113.39 Billion | +29.06% |
| 2017 | $87.85 Billion | +52.03% |
| 2016 | $57.79 Billion | -12.32% |
| 2015 | $65.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Abbott Laboratories was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $177.76 Billion USD |
| MoneyControl | $177.76 Billion USD |
| MarketWatch | $177.76 Billion USD |
| marketcap.company | $177.76 Billion USD |
| Reuters | $177.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more